Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137914 | 0.88 | CHRM5 (0.48) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL5949588 | 0.84 | CHRM5 (0.52) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL5376134 | 0.83 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL11596303 | 0.83 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL41997 | 0.82 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL1515104 | 0.80 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL3439903 | 0.80 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL20643257 | 0.80 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL3439882 | 0.80 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL30340995 | 0.80 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11731947-B2 | Deuterated antimicrobial compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-22 | — | — | US | claimed |
| US-20220204463-A1 | DEUTERATED ANTIMICROBIAL COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-06-30 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2020210125-A1 | DEUTERATED ANTIMICROBIAL COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3515920-A1 | NEW ANTIMICROBIAL COMPOUNDS, THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS AND A NEW METABOLIC MECHANISM | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2019-07-31 | — | — | EP | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| WO-2018055048-A1 | NEW ANTIMICROBIAL COMPOUNDS, THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS AND A NEW METABOLIC MECHANISM | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL INSTITUT (HKI) (DE) | 2018-03-29 | — | — | WO | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| US-7943605-B2 | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses | UCB PHARMA S.A. (BE) | 2011-05-17 | — | — | US | claimed |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | claimed |
| EP-1943217-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-07-16 | — | — | EP | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204463-A1 | DEUTERATED ANTIMICROBIAL COMPOUNDS | TALDO1, TXNRD1, NQO1 | CHRM5 4385/4885ADRA2C 2432/4885ACHE 3311/4885 |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CHRM5 140/4885ADRA2C 314/4885ACHE 136/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | CHRM5 1450/4885ADRA2C 2577/4885ACHE 18/4885 |
| US-11731947-B2 | Deuterated antimicrobial compounds | TALDO1, TXNRD1, TXNRD3 | CHRM5 4438/4885ADRA2C 2354/4885ACHE 3409/4885 |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | COASY, FURIN, PEPD | CHRM5 4048/4885ADRA2C 3275/4885ACHE 194/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | CHRM5 322/4885ADRA2C 114/4885ACHE 98/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | CHRM5 2067/4885ADRA2C 357/4885ACHE 2716/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CHRM5 140/4885ADRA2C 314/4885ACHE 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.